688185 康希诺
交易中 07-13 13:01:27
资讯
新帖
简况
每周股票复盘：康希诺（688185）H股及A股股本无变动
证券之星 · 07-05
每周股票复盘：康希诺（688185）H股及A股股本无变动
康希诺：三组分百白破疫苗预计7月可获得批签发
经济参考网 · 07-04
康希诺：三组分百白破疫苗预计7月可获得批签发
康希诺（688185）披露截至2026年6月30日证券变动月报表，7月3日股价上涨1.28%
证券之星 · 07-03
康希诺（688185）披露截至2026年6月30日证券变动月报表，7月3日股价上涨1.28%
6月29日康希诺涨7.35%，广发科创板两年定开混合基金重仓该股
证券之星 · 06-29
6月29日康希诺涨7.35%，广发科创板两年定开混合基金重仓该股
每周股票复盘：康希诺（688185）脑膜炎疫苗获阿根廷注册证
证券之星 · 06-28
每周股票复盘：康希诺（688185）脑膜炎疫苗获阿根廷注册证
康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)获得阿根廷注册证书
智通财经 · 06-25
康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)获得阿根廷注册证书
股市必读：康希诺（688185）6月16日董秘有最新回复
证券之星 · 06-17
股市必读：康希诺（688185）6月16日董秘有最新回复
康希诺：以WHO PQ为方向进行前期准备和筹划工作
证券之星 · 06-16
康希诺：以WHO PQ为方向进行前期准备和筹划工作
康希诺新提交“未公开”、“泰特欣”等5件商标注册申请
证券之星 · 06-14
康希诺新提交“未公开”、“泰特欣”等5件商标注册申请
每周股票复盘：康希诺（688185）H股及A股股本无变动
证券之星 · 06-07
每周股票复盘：康希诺（688185）H股及A股股本无变动
每周股票复盘：康希诺（688185）24价肺炎疫苗启动临床试验
证券之星 · 05-31
每周股票复盘：康希诺（688185）24价肺炎疫苗启动临床试验
康希诺跌4.11% 2020年上市募52亿元中信证券保荐
中金财经 · 05-28
康希诺跌4.11% 2020年上市募52亿元中信证券保荐
康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组
智通财经 · 05-25
康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组
每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元
证券之星 · 05-24
每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元
康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%
证券之星 · 05-20
康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%
康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品
证券日报 · 05-13
康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品
康希诺跌1.71% 2020年上市募52亿元中信证券保荐
中金财经 · 05-13
康希诺跌1.71% 2020年上市募52亿元中信证券保荐
康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种
证券之星 · 05-11
康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种
5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股
证券之星 · 05-11
5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股
每周股票复盘：康希诺（688185）H股公众持股量合规
证券之星 · 05-10
每周股票复盘：康希诺（688185）H股公众持股量合规
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":49.94,"timestamp":1783918887000,"preClose":51.28,"halted":0,"volume":1441873,"delay":0,"changeRate":-0.0261,"floatShares":113999999,"shares":247000000,"eps":-0.0041,"marketStatus":"交易中","change":-1.34,"latestTime":"07-13 13:01:27","open":51.3,"high":52.3,"low":49.59,"amount":73104300,"amplitude":0.0528,"askPrice":49.95,"askSize":16,"bidPrice":49.84,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.0041,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783926000000},"marketStatusCode":2,"adr":0,"adjPreClose":51.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783906200000,1783913400000],[1783918800000,1783926000000]],"highLimit":56.41,"lowLimit":46.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":2.57,"roa":"--","roe":"--","epsLYR":0.11,"committee":-0.058824,"marketValue":12337000000,"turnoverRate":0.0126,"status":1,"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":23.08,"timestamp":1783918828432,"preClose":23.42,"halted":0,"volume":447600,"delay":0,"premium":"-59.99"},"floatMarketCap":5712000000},"requestUrl":"/m/hq/s/688185/wiki","defaultTab":"wiki","newsList":[{"id":"2649692485","title":"每周股票复盘：康希诺（688185）H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649692485?lang=zh_cn&edition=full","pubTime":"2026-07-05 04:12","pubTimestamp":1783195933,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，康希诺报收于53.05元，较上周的47.9元上涨10.75%。H股总数为132,670,900股，于香港联交所上市；A股总数为1114,372,901股，在上海证券交易所科创板上市。股份期权计划方面，2025年核心管理层H股购股权计划项下存续的股份期权为860,000股，本月无新增或注销。2025年A股限制性股票激励计划项下，首次授予的2,054,600股限制性股票状态维持不变。公司确认H股类别已满足公众持股量要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","399300","BK0239","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648269932","title":"康希诺：三组分百白破疫苗预计7月可获得批签发","url":"https://stock-news.laohu8.com/highlight/detail?id=2648269932","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648269932?lang=zh_cn&edition=full","pubTime":"2026-07-04 18:26","pubTimestamp":1783160768,"startTime":"0","endTime":"0","summary":"【康希诺：三组分百白破疫苗预计7月可获得批签发】康希诺生物股份公司在7月3日发布的投资者活动关系记录表中表示，目前，公司研发的婴幼儿三组分百白破DT3cP盼康欣的批签发和各地招标准入的相关工作正在有序进行当中。截至目前，盼康欣已在几个省份获得准入，预计7月可获得首批批签发放行。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607043794196135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159646","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648664808","title":"康希诺（688185）披露截至2026年6月30日证券变动月报表，7月3日股价上涨1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648664808","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648664808?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:55","pubTimestamp":1783090517,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，康希诺报收于53.05元，较前一交易日上涨1.28%，最新总市值为131.06亿元。近日，康希诺生物股份公司披露截至2026年6月30日的证券变动月报表。H股总数为132,670,900股，于香港联交所上市；A股总数为1114,372,901股，在上海证券交易所科创板上市。股份期权计划方面，2025年核心管理层H股购股权计划项下存续的股份期权为860,000股，本月无新增或注销。2025年A股限制性股票激励计划项下，首次授予的2,054,600股限制性股票状态维持不变。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300046124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324228","title":"6月29日康希诺涨7.35%，广发科创板两年定开混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324228?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:37","pubTimestamp":1782722247,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日康希诺涨7.35%创60日新低，收盘报51.42元，换手率2.66%，成交量3.04万手，成交额1.53亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发科创板两年定开混合。广发科创板两年定开混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646316864","title":"每周股票复盘：康希诺（688185）脑膜炎疫苗获阿根廷注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2646316864","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646316864?lang=zh_cn&edition=full","pubTime":"2026-06-28 04:00","pubTimestamp":1782590442,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，康希诺报收于47.9元，较上周的49.93元下跌4.07%。本周关注点公司公告汇总：ACYW135群脑膜炎球菌疫苗获阿根廷注册证书。公司公告汇总自愿披露关于ACYW135群脑膜炎球菌多糖结合疫苗获得阿根廷注册证书的公告康希诺生物股份公司公告，其ACYW135群脑膜炎球菌多糖结合疫苗，商品名为曼海欣，近日获得阿根廷国家药品、食品和医疗器械管理局颁发的注册证书。产品在阿根廷的实际销售时间及金额尚存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688185","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875454","title":"康希诺(688185.SH)：ACYW135群脑膜炎球菌多糖结合疫苗(CRM197载体)获得阿根廷注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875454","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646875454?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:04","pubTimestamp":1782378257,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺 发布公告，公司的ACYW135群脑膜炎球菌多糖结合疫苗于近日获得阿根廷国家药品、食品和医疗器械管理局授予的注册证书。曼海欣7-59岁扩龄临床研究已取得临床总结报告，正在开展补充申请相关准备。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644081764","title":"股市必读：康希诺（688185）6月16日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644081764","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644081764?lang=zh_cn&edition=full","pubTime":"2026-06-17 02:32","pubTimestamp":1781634731,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，康希诺报收于49.97元，下跌0.79%，换手率1.05%，成交量1.2万手，成交额5989.94万元。董秘最新回复投资者： 您好，贵司四价流脑结合疫苗，13价肺炎结合疫苗，婴幼儿组分百白破疫苗，是否考虑WHO PQ预认证，以扩大全球供应？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700001011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753746","title":"康希诺：以WHO PQ为方向进行前期准备和筹划工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753746?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:03","pubTimestamp":1781604207,"startTime":"0","endTime":"0","summary":"康希诺回复：尊敬的投资人您好，公司当前结合四价流脑结合疫苗、13价肺炎结合疫苗以及组分百白破疫苗组合的海外开拓目标，以公司丰富的产品管线为切入点，与合作方建立长期良好的战略合作关系，探索技术转移的合作模式，推进公司国际化进程。同时，公司也会视产品定位及研发进度，以世界卫生组织预认证为方向进行前期准备和筹划工作，探索国际组织采购产品的可行性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643124248","title":"康希诺新提交“未公开”、“泰特欣”等5件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2643124248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643124248?lang=zh_cn&edition=full","pubTime":"2026-06-14 06:36","pubTimestamp":1781390178,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日康希诺生物股份公司新提交“未公开”、“泰特欣”等5件商标注册申请。商标申请详情如下：今年以来康希诺生物股份公司新申请注册商标5件，截止目前公司共持有注册商标176件，另有155件商标尚在注册申请中。结合公司2025年年报财务数据，2025年公司在研发方面投入了3.13亿元，同比减24.77%。通过天眼查大数据分析，康希诺生物股份公司共对外投资了10家企业，参与招投标项目566次；财产线索方面有商标信息288条，专利信息110条，著作权信息15条；此外企业还拥有行政许可618个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061400000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641540127","title":"每周股票复盘：康希诺（688185）H股及A股股本无变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2641540127","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641540127?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:20","pubTimestamp":1780770023,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，康希诺报收于52.16元，较上周的58.55元下跌10.91%。股份期权计划方面，2025年核心管理层H股购股权计划项下结存期权为860,000股，无新增行使。2025年A股限制性股票激励计划涉及2,054,600股，本月无新增发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","399300","688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604189","title":"每周股票复盘：康希诺（688185）24价肺炎疫苗启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604189?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:29","pubTimestamp":1780169350,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，康希诺报收于58.55元，较上周的62.4元下跌6.17%。本周，康希诺5月25日盘中最高价报65.35元。康希诺当前最新总市值144.64亿元，在生物制品板块市值排名19/51，在两市A股市值排名1459/5207。本周关注点公司公告汇总：康希诺24价肺炎球菌多糖结合疫苗启动I/II期临床试验并完成首例受试者入组。公司已有13价肺炎疫苗优佩欣获批上市。截至目前，国内外尚无24价肺炎疫苗上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653476","title":"康希诺跌4.11% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653476","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638653476?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:17","pubTimestamp":1779956248,"startTime":"0","endTime":"0","summary":"中国经济网北京5月28日讯 康希诺 今日收报57.91元，跌幅4.11%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260528/32261285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1580142542.USD","BK1147","LU1064131003.USD","LU2495084118.USD","LU1794554557.SGD","LU1997244956.HKD","688185","LU1255011170.USD","LU1997245177.USD","LU2148510915.USD","LU0405327494.USD","BK0276","BK1564","LU1655091616.SGD","600030","BK0028","BK0239","LU1781817850.SGD","LU1720050803.USD","LU1997245094.SGD","BK0012","BK1516","BK0183","BK1521","LU1064130708.USD","06030","LU0405327148.USD","IPOS","LU1328615791.USD","BK0188","BK0196","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535415","title":"康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535415","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535415?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:11","pubTimestamp":1779696668,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布公告，公司的24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)(简称“PCV24”)于近日正式启动I/II期临床试验，并完成首例受试者入组。I/II期临床试验为评价PCV24在2月龄(最小6周)及以上人群中接种后安全性与免疫原性的随机、盲法、剂量探索、阳性对照的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)：24价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)启动I/II期临床试验并完成首例受试者入组","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","159646","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637920375","title":"每周股票复盘：康希诺（688185）拟审议未弥补亏损超4.7亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637920375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637920375?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:52","pubTimestamp":1779565933,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，康希诺报收于62.4元，较上周的59.98元上涨4.03%。本周，康希诺5月19日盘中最高价报68.48元。康希诺生物股份公司召开2025年年度股东会，审议2025年度董事会工作报告、年度报告及利润分配方案等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636848150","title":"康希诺（688185）披露2025年年度股东会会议资料，5月20日股价下跌2.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636848150","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636848150?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:48","pubTimestamp":1779270495,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，康希诺报收于63.13元，较前一交易日下跌2.46%，最新总市值为155.96亿元。该股当日开盘64.4元，最高66.47元，最低62.53元，成交额达2.07亿元，换手率为2.82%。康希诺生物股份公司于2026年5月20日披露《2025年年度股东会会议资料》。公告显示，公司拟召开2025年年度股东会，审议2025年度董事会工作报告、年度报告及利润分配方案等议案。公司2025年末合并未分配利润为-471,443,086.47元，实收股本总额三分之一以上为未弥补亏损，故提请股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635738813","title":"康希诺：公司将在做好主营业务的基础之上，探索治疗领域的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2635738813","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635738813?lang=zh_cn&edition=full","pubTime":"2026-05-13 21:30","pubTimestamp":1778679000,"startTime":"0","endTime":"0","summary":"证券日报网讯5月13日，康希诺在互动平台回答投资者提问时表示，公司将在做好主营业务的基础之上，探索治疗领域的产品，目前正在推进mRNA疫苗用于治疗胶质母细胞瘤以及横纹肌肉瘤等适应症的研发工作，同时会持续布局候选产品线。公司也会根据不同的产品特性、竞争格局及未来价值前景等，拥抱潜在的合作机会及各种可能性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133736241467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635520949","title":"康希诺跌1.71% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2635520949","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635520949?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:56","pubTimestamp":1778658975,"startTime":"0","endTime":"0","summary":"中国经济网北京5月13日讯 康希诺 今日股价下跌，截至收盘，该股报63.80元，跌幅1.71%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260513/32220631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1521","BK0183","LU1794554557.SGD","BK1516","LU1997245177.USD","688185","LU1580142542.USD","LU1328615791.USD","LU1655091616.SGD","06030","BK0012","LU1720050803.USD","LU0405327494.USD","BK0188","BK1147","BK0028","LU1781817850.SGD","LU1064131003.USD","BK0239","BK0196","LU1997244956.HKD","LU1997245094.SGD","LU1064130708.USD","LU2148510915.USD","LU1255011170.USD","BK1564","LU2289578879.USD","BK0276","LU0405327148.USD","600030","LU2495084118.USD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404991","title":"康希诺最新公告：青少年及成人用百白破疫苗纳入优先审评品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404991","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404991?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:22","pubTimestamp":1778491361,"startTime":"0","endTime":"0","summary":"康希诺(688185.SH)公告称，公司研发的吸附无细胞百(五组分)白破联合疫苗(6岁及以上人群用)已正式纳入国家药监局药品审评中心优先审评品种。该疫苗适用于青少年及成人加强免疫，国内暂无同类获批产品，若成功上市将填补市场空白。公司正准备该产品的上市许可申请递交工作，但后续审评进度及获批时间存在不确定性，对近期业绩无重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100023814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","688185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409601","title":"5月11日康希诺涨7.96%，广发科创板两年定开混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409601?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:29","pubTimestamp":1778488190,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日康希诺涨7.96%，收盘报67.7元，换手率5.13%，成交量5.87万手，成交额3.89亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发科创板两年定开混合。广发科创板两年定开混合目前规模为1.21亿元，最新净值1.357，较上一交易日下跌1.65%，近一年上涨61.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634412551","title":"每周股票复盘：康希诺（688185）H股公众持股量合规","url":"https://stock-news.laohu8.com/highlight/detail?id=2634412551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634412551?lang=zh_cn&edition=full","pubTime":"2026-05-10 03:18","pubTimestamp":1778354291,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，康希诺报收于62.71元，较上周的61.51元上涨1.95%。本周，康希诺5月8日盘中最高价报62.99元。康希诺当前最新总市值154.92亿元，在生物制品板块市值排名20/51，在两市A股市值排名1426/5200。公司确认H股类别已符合联交所规定的公众持股量要求。股份期权方面，2025年核心管理层H股购股权计划项下有860,000份期权，本月无变动。2025年A股限制性股票激励计划涉及2,054,600股，本月未新增发行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000001307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783918912485,"stockEarnings":[{"period":"1week","weight":-0.0334},{"period":"1month","weight":0.0165},{"period":"3month","weight":-0.2316},{"period":"6month","weight":-0.2535},{"period":"1year","weight":-0.16},{"period":"ytd","weight":-0.1841}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16477人(较上一季度增加Infinity%)","perCapita":"6941股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是疫苗销售、药品生产工艺研究开发业务、技术转移及中间品销售。公司自主研发的“多糖蛋白结合疫苗关键技术及产业化”项目荣获天津市科学技术进步一等奖。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}